Triad Isotopes, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Triad Isotopes, Inc. - overview
Location
Orlando, FL, US
Primary Industry
Pharmaceuticals
About
Triad Isotopes, Inc. is a leading provider of radiopharmaceuticals, focusing on nuclear medicine solutions for imaging and treatment. The company supports healthcare providers with a diverse range of products essential for patient diagnostics and care. Triad Isotopes, Inc.
specializes in radiopharmaceuticals, operating primarily in the United States with its headquarters in Orlando, FL. The company was founded to provide essential nuclear medicine products and has a notable presence in the market. It has successfully executed 2 deals with Parthenon Capital Partners, which recently exited its stake in the firm, though financial terms were not disclosed. Triad Isotopes, Inc.
offers a comprehensive range of FDA-approved radiopharmaceutical products for nuclear medicine applications, including Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT). Their open formulary approach enables healthcare professionals to select from a wide array of options tailored to enhance patient outcomes. With over 50 locations, they efficiently serve hospitals, outpatient imaging centers, and medical clinics throughout the United States. Triad Isotopes, Inc.
generates revenue through a direct-to-consumer model and partnerships with healthcare providers, focusing on the procurement and delivery of radiopharmaceuticals for use in diagnostic and therapeutic procedures. Their sales structure is centered around individual product sales tailored to the specific needs of clients, including flagship products like PSMA-11 for prostate cancer imaging, fostering long-term relationships with healthcare professionals and ensuring steady revenue within the nuclear medicine sector. Triad Isotopes, Inc. is actively developing new radiopharmaceutical products to expand its offerings in nuclear medicine.
The company plans to enter new geographic markets, enhancing its service capabilities across various regions in the United States. Recent funding from Parthenon Capital Partners will support these initiatives, further establishing their footprint in the industry.
Primary Industry
Pharmaceuticals
Sub Industries
Healthcare, Specialty Pharmaceuticals
Website
www.triadisotopes.com
Total Amount Raised
Subscriber access only
Triad Isotopes, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Covidien Radiopharmacies | - | ||||||||
| Growth | Completed | Triad Isotopes, Inc. | - | ||||||||
| Unspecified Exit | Completed | Triad Isotopes, Inc. | - |
Displaying 1 - 3 of 3
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.